Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have type 1 diabetes. Regulatory submissions are expected in 2026, and if ...

Mosaic Therapeutics has secured the latest pieces in its combination medicine strategy by licensing two clinical stage tumor ...

Höegh Evi, in partnership with Wärtsilä Gas Solutions, has announced the completion of the world’s first floating ...

Discover how IVBT impacts long-term outcomes in complex in-stent restenosis—read the full report for key clinical insights.